e-learning
resources
Madrid 2019
Sunday, 29.09.2019
The changing face of rare diffuse parenchymal lung diseases: recent advances in pathogenesis, clinical manifestations and treatment
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Assessment of Treatment Response in Granulomatous Lymphocytic Interstitial Lung Disease (GLILD)
G. Gkrepi (Andros, Greece), D. Lowe (London, United Kingdom), S. Burns (London, United Kingdom), S. Seneviratne (London, United Kingdom), J. Hurst (London, United Kingdom)
Source:
International Congress 2019 – The changing face of rare diffuse parenchymal lung diseases: recent advances in pathogenesis, clinical manifestations and treatment
Session:
The changing face of rare diffuse parenchymal lung diseases: recent advances in pathogenesis, clinical manifestations and treatment
Session type:
Thematic Poster
Number:
1408
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
G. Gkrepi (Andros, Greece), D. Lowe (London, United Kingdom), S. Burns (London, United Kingdom), S. Seneviratne (London, United Kingdom), J. Hurst (London, United Kingdom). Assessment of Treatment Response in Granulomatous Lymphocytic Interstitial Lung Disease (GLILD). 1408
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ANCA associated vasculitis and lung disease
Panel discussion on genetics in pulmonary fibrosis
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Related content which might interest you:
Modes of Disease Progression in Different Forms of Interstitial Lung Disease with Usual Interstitial Pneumonia Histology in Patients with Idiopathic and Non-idiopathic Etiologies - A Single Center Experience
Source: International Congress 2019 – Immune-mediated interstitial lung diseases: from bench to bedside
Year: 2019
A Comparison of Pulmonary Rehabilitation Outcomes in Interstitial Lung Disease and Chronic Obstructive Pulmonary Disease
Source: International Congress 2019 – Pulmonary rehabilitation for non-obstructive lung diseases
Year: 2019
Predictive Findings of Progressive Fibrosing Interstitial Lung Disease (PF-ILD)
Source: Virtual Congress 2021 – Prognostic markers of disease progression in non-idiopathic pulmonary fibrosis interstitial lung diseases
Year: 2021
Development Of A Machine Learning Combination With Deep Learning For Diagnosing Idiopathic Pulmonary Fibrosis In Chronic Interstitial Lung Disease
Source: Virtual Congress 2020 – Predictive markers of progression in connective tissue disease-associated interstitial lung disease and hypersensitivity pneumonitis
Year: 2020
Comparison of Eosinophilic and Non-eosinophilic Cases with Chronic Obstructive Pulmonary Disease (COPD) in terms of Clinical Arrival, Exacerbations, Quality of Life and Response to Treatment: A Prospective Study
Source: International Congress 2019 – Airway diseases and blood cells
Year: 2019
Diffuse Pulmonary Non-Amyloid Light-Chain Deposition Disease: Phenotypes and Outcome
Source: Virtual Congress 2021 – Exploring the phenotypic heterogeneity across rare diffuse parenchymal lung diseases
Year: 2021
Risk Factor for Chronic Obstructive Pulmonary Disease in Never-Smoker Patients with Non-Cystic Fibrosis Bronchiectasis
Source: International Congress 2019 – Bronchiectasis
Year: 2019
A First-in-Class PRS Inhibitor, DWN12088, as a Novel Therapeutic Agent for Systemic Sclerosis and Associated Interstitial Lung Disease
Source: Virtual Congress 2021 – Exploring the phenotypic heterogeneity across rare diffuse parenchymal lung diseases
Year: 2021
Cognitive failure in sarcoidosis
Source: International Congress 2014 – Sarcoidosis
Year: 2014
Clinical Features and Prognosis of Acute exacerbation of Connective Tissue Diseases Associated Pulmonary Fibrosis------ Comparision with Idiopathic Pulmonary Fibrosis
Source: International Congress 2017 – The spectrum of CTDs: from pathogenesis to treatment
Year: 2017
The incidence of Progressive Fibrotic Interstitial Lung Diseases (PFILD) treatable with oral-antifibrotic therapy in a UK Specialist Interstitial Lung Disease clinic.
Source: Virtual Congress 2020 – Idiopathic pulmonary fibrosis and interstitial lung disease: progression, genes and more
Year: 2020
LATE-BREAKING ABSTRACT: Efficacy of Pirfenidone for Idiopathic Pulmonary Fibrosis (IPF): an Italian real life study
Source: International Congress 2014 – IPF and surroundings
Year: 2014
Impact of Pulmonary Hypertension on the Response to Pulmonary Rehabilitation in Obstructive Lung Disease
Source: International Congress 2019 – The future of pulmonary rehabilitation discussed today
Year: 2019
Study to Evaluate Satisfaction with the Inhalation Device Used by Patients with Asthma or Chronic Obstructive Pulmonary Disease and the Association with Adherence and Disease Control
Source: Virtual Congress 2020 – Novel insights into nursing interventions for managing patients with asthma and COPD
Year: 2020
The Effects Of Bronchiectasis Severity On Outcomes Of Chronic Obstructive Pulmonary Disease Exacerbation
Source: International Congress 2017 – Imaging markers for COPD and asthma
Year: 2017
From the Cradle to the Grave - The Early-Life Origins of Chronic Obstructive Pulmonary Disease
Source: Virtual Congress 2020 - Pre-reading material
Year: 2020
Clinical Features and Treatment Outcome of Carcinomatous Pericarditis due to Lung Cancer.
Source: International Congress 2018 – Lung cancer: modern therapies and beyond
Year: 2018
Management of spontaneous pneumothorax in patients with or without Birt-Hogg-Dubé syndrome
Source: International Congress 2014 – ILDs 1
Year: 2014
Association of Metabolic Syndrome with the severity of Chronic Obstructive Pulmonary Disease
Source: Virtual Congress 2020 – Clinical data and COPD management
Year: 2020
Low Level of Airway Mucin 2 Predict Severe Exacerbations in Patients with Severe Chronic Obstructive Pulmonary Disease
Source: International Congress 2017 – COPD biomarkers
Year: 2017
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept